Research-grade peptide intelligence, delivered every Tuesday. Deep analysis, study breakdowns, and regulatory updates.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
Tirzepatide and semaglutide tie on cardiovascular outcomes despite different mechanisms. The GIP question, dosing framework, PCAC deadline.
Retatrutide hits 30.3% weight loss at two years. Thymosin Alpha-1 fails Phase 3. Kisspeptin goes nasal. FDA PCAC July agenda confirmed.
Survodutide Phase 2 MASH data, why the second receptor matters, and the complete 12-peptide FDA list from April 15.
Orforglipron FDA approved. Seven peptides going to advisory panel in July. Here is what both announcements actually mean.
CagriSema Phase 3 results, retatrutide TRIUMPH-4, SS-31 FDA approval, and what the Category 2 reclassification actually means.